<DOC>
	<DOCNO>NCT01381094</DOCNO>
	<brief_summary>The purpose study evaluate dose response ( efficacy ) , safety , tolerability orally administer AKB-6548 pre-dialysis subject anemia repeat dose 42 day .</brief_summary>
	<brief_title>42-Day Repeat Oral Dose Study AKB-6548 Subjects With Chronic Kidney Disease Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Key 18 79 year age , inclusive Chronic Kidney Disease ( eGFR &lt; 60 mL/min ) , yet dialysis Hemoglobin ( Hgb ) ≤ 10.5 g/dL TSAT ≥ 20 % Ferritin ≥ 50 ng/mL Key BMI &gt; 42 Red blood cell transfusion within 12 week Androgen therapy within previous 21 day prior study dose Therapy approve experimental erythropoiesis stimulate agent ( ESA ) within 11 week prior Screening visit Subjects meet criterion ESA resistance within previous 4 month Individual dos intravenous iron great 250 mg within past 21 day AST ALT &gt; 1.8x ULN Alkaline phosphatase &gt; 2x ULN Total bilirubin &gt; 1.5x ULN Uncontrolled hypertension New York Heart Association Class III IV congestive heart failure Myocardial infarction , acute coronary syndrome , stroke within 6 month prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>